- Home
- HBB vs DCTH Comparison
HBB vs DCTH Comparison
Compare HBB & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBB
- DCTH
- Stock Information
- Founded
- HBB 1904
- DCTH 1988
- Country
- HBB United States
- DCTH United States
- Employees
- HBB N/A
- DCTH N/A
- Industry
- HBB Home Furnishings
- DCTH Medical/Dental Instruments
- Sector
- HBB Consumer Discretionary
- DCTH Health Care
- Exchange
- HBB Nasdaq
- DCTH Nasdaq
- Market Cap
- HBB 242.8M
- DCTH 630.4M
- IPO Year
- HBB 2017
- DCTH N/A
- Fundamental
- Price
- HBB $18.11
- DCTH $12.76
- Analyst Decision
- HBB
- DCTH Strong Buy
- Analyst Count
- HBB 0
- DCTH 4
- Target Price
- HBB N/A
- DCTH $24.00
- AVG Volume (30 Days)
- HBB 26.4K
- DCTH 748.0K
- Earning Date
- HBB 07-30-2025
- DCTH 08-04-2025
- Dividend Yield
- HBB 2.67%
- DCTH N/A
- EPS Growth
- HBB 18.18
- DCTH N/A
- EPS
- HBB 2.43
- DCTH N/A
- Revenue
- HBB $659,788,000.00
- DCTH $53,850,000.00
- Revenue This Year
- HBB N/A
- DCTH $155.42
- Revenue Next Year
- HBB N/A
- DCTH $37.93
- P/E Ratio
- HBB $7.38
- DCTH N/A
- Revenue Growth
- HBB 5.46
- DCTH 1068.87
- 52 Week Low
- HBB $13.25
- DCTH $7.17
- 52 Week High
- HBB $31.78
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- HBB 52.17
- DCTH 32.99
- Support Level
- HBB $17.41
- DCTH $13.30
- Resistance Level
- HBB $18.49
- DCTH $14.15
- Average True Range (ATR)
- HBB 0.86
- DCTH 0.66
- MACD
- HBB 0.05
- DCTH -0.27
- Stochastic Oscillator
- HBB 62.15
- DCTH 2.91
About HBB Hamilton Beach Brands Holding Company
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products and Health.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.